News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Reinforcing commitment to ethical and sustainable growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Subscribe To Our Newsletter & Stay Updated
